Skip to main content
. 2021 Oct 20;10(21):e022274. doi: 10.1161/JAHA.121.022274

Figure 5. Timeline showing important dates of left atrial appendage occlusion trials and US FDA milestones in the United States.

Figure 5

AF indicates atrial fibrillation; ASAP, ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology; ASAP TOO, The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation; CAP, Continued Access to PROTECT AF; CAP2, Continued Access to PREVAIL; CE, conformité européenne; EXCLUDE, Exclusion of Left Atrial Appendage with AtriClip Exclusion Device in Patients Undergoing Concomitant Cardiac Surgery; FDA, Food and Drug Administration; LAA, left atrial appendage; LAAOS I, Left Atrial Appendage Occlusion During Cardiac Surgery to Prevent Stroke; and PLAATO, percutaneous left atrial appendage transcatheter occlusion.